Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
Silexion Therapeutics Corp. (SLXN), a clinical-stage oncology-focused biotech company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.
Key points:
- Company presentation will be available on-demand starting September 9 at 7:00 AM ET
- Management team will be available for one-on-one meetings during the conference
- Investors interested in meetings should contact their H.C. Wainwright representative
- A replay of the presentation will be accessible on Silexion's website for 90 days
This conference provides Silexion an opportunity to showcase its progress and engage with potential investors in the oncology therapeutics sector.
Silexion Therapeutics Corp. (SLXN), una compagnia biotecnologica focalizzata sull'oncologia in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Globale Annuale di Investimento H.C. Wainwright. L'evento si terrà dal 9 all'11 settembre 2024 presso il Lotte New York Palace Hotel a New York, NY.
Punti chiave:
- La presentazione dell'azienda sarà disponibile on-demand a partire dal 9 settembre alle 7:00 AM ET
- Il team di gestione sarà disponibile per incontri one-to-one durante la conferenza
- Gli investitori interessati agli incontri devono contattare il proprio rappresentante H.C. Wainwright
- Una registrazione della presentazione sarà accessibile sul sito web di Silexion per 90 giorni
Questa conferenza offre a Silexion un'opportunità per mostrare i propri progressi e interagire con potenziali investitori nel settore delle terapie oncologiche.
Silexion Therapeutics Corp. (SLXN), una compañía biofarmacéutica centrada en oncología en etapa clínica, ha anunciado su participación en la 26ª Conferencia Anual Global de Inversión H.C. Wainwright. El evento está programado para del 9 al 11 de septiembre de 2024 en el Lotte New York Palace Hotel en Nueva York, NY.
Puntos clave:
- La presentación de la empresa estará disponible bajo demanda a partir del 9 de septiembre a las 7:00 AM ET
- El equipo de gestión estará disponible para reuniones uno a uno durante la conferencia
- Los inversores interesados en reuniones deben contactar a su representante de H.C. Wainwright
- Una repetición de la presentación estará accesible en el sitio web de Silexion por 90 días
Esta conferencia brinda a Silexion la oportunidad de mostrar sus avances y relacionarse con inversores potenciales en el sector de terapias oncológicas.
Silexion Therapeutics Corp. (SLXN), 임상 단계의 항암 생명과학 회사,가 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕, NY의 로테 뉴욕 팰리스 호텔에서 개최됩니다.
주요 사항:
- 회사의 발표는 9월 9일 오전 7시 ET부터 주문형으로 제공됩니다
- 경영진 팀은 회의 동안 일대일 미팅을 위해 대기할 것입니다
- 미팅에 관심 있는 투자자는 H.C. Wainwright 담당자에게 연락해야 합니다
- 발표 재생은 Silexion 웹사이트에서 90일 동안 이용 가능합니다
이번 회의는 Silexion이 진행 상황을 보여주고 항암 치료 분야의 잠재 투자자들과 소통할 수 있는 기회를 제공합니다.
Silexion Therapeutics Corp. (SLXN), une entreprise biopharmaceutique axée sur l'oncologie en phase clinique, a annoncé sa participation à la 26e Conférence Annuelle Mondiale d'Investissement H.C. Wainwright. L'événement est prévu du 9 au 11 septembre 2024 à l'Hôtel Lotte New York Palace à New York, NY.
Points clés :
- La présentation de l'entreprise sera disponible à la demande à partir du 9 septembre à 7h00 ET
- La direction sera disponible pour des réunions individuelles pendant la conférence
- Les investisseurs intéressés par des réunions doivent contacter leur représentant H.C. Wainwright
- Un replay de la présentation sera accessible sur le site Web de Silexion pendant 90 jours
Cette conférence offre à Silexion une occasion de mettre en avant ses progrès et d'engager un dialogue avec des investisseurs potentiels dans le secteur des thérapies oncologiques.
Silexion Therapeutics Corp. (SLXN), ein biopharmazeutisches Unternehmen, das sich auf die Onkologie in der klinischen Phase konzentriert, hat seine Teilnahme an der 26. jährlichen globalen Investmentkonferenz von H.C. Wainwright angekündigt. Die Veranstaltung findet vom 9. bis 11. September 2024 im Lotte New York Palace Hotel in New York, NY statt.
Wichtige Punkte:
- Die Unternehmenspräsentation wird ab 9. September um 7:00 Uhr ET auf Abruf verfügbar sein
- Das Managementteam wird während der Konferenz für Einzelgespräche zur Verfügung stehen
- Investoren, die an Meetings interessiert sind, sollten ihren H.C. Wainwright-Vertreter kontaktieren
- Eine Wiederholung der Präsentation wird für 90 Tage auf der Website von Silexion verfügbar sein
Diese Konferenz bietet Silexion die Möglichkeit, seine Fortschritte zu präsentieren und mit potenziellen Investoren im Bereich der Onkologie-Therapien in Kontakt zu treten.
- None.
- None.
GRAND CAYMAN, Cayman Island, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company today announced that Company management will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.
A company presentation will be available on demand here as of Monday, September 9 at 7:00 AM ET. Silexion’s management team will be available for one-on-one meetings during the conference, interested investors should contact their representative at H.C. Wainwright. A replay of the presentation will be posted, when available, to Silexion’s website on the Presentation & Events page of the investors section for 90 days.
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer.
Contacts
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Investors
Chuck Padala
LifeSci Advisors
Chuck@lifesciadvisors.com
FAQ
When is Silexion Therapeutics (SLXN) presenting at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright 26th Annual Global Investment Conference being held?
Can investors meet with Silexion Therapeutics (SLXN) management at the conference?
How long will Silexion Therapeutics' (SLXN) presentation be available for viewing after the conference?
